Many of the more sophisticated forms of medicine, including gene therapies and immunotherapies, are challenging to deliver to the brain. At the very least there are far fewer practical options for delivery, and it is possible that none of that that exist fit a given desired use case. The blood-brain barrier stands in the way of intravenous injection as a path for most approaches, blocking passage of most cells and molecules from circulation to brain tissue. While direct injection into the brain or into reservoirs of cerebrospinal fluid can be achieved, they are sufficiently invasive and challenging to rule out commonplace use.
The brain is made up of many different cell types, and more sophisticated approaches will want specificity to regions or cell types. Small molecules can readily pass everywhere in the body, but are a poor tool if the goal is to engineer selective activity in a given cell type. That selectivity is readily achievable via any form of gene therapy in which expression is keyed to a promoter only active in the cell type of interest. But gene therapies with that capability are largely very hard to get into the brain, or have other characteristics that present hurdles. Forms of AAV viral vectors now exist that can pass the blood-brain barrier, but AAV is restricted in size of payload, and payload size is required for promoter-driven selectivity, ability to turn off the therapy at any point, and other add-ons.
So it is always interesting to see people trying new approaches. Today's open access paper presents a way to selectively deliver antibodies via intravenous injection, through the blood-brain barrier, and into astrocytes in the brain. The astrocytes are reprogrammed into neurons that integrate into existing neural networks and reverse loss of cognitive function. The treatment is focused on Alzheimer's disease, and given the artificiality of the mouse models of this condition, it is always good to wait for a while before becoming too excited by any claimed advance. All too many approaches improve the mice, but do not work well in the human condition. More generally, a feasible approach to deliver antibodies to degrade a specific protein in a specific set of brain cells is quite an interesting technology, however.
Reverse the progression of Alzheimer's disease through Nano-ERASER-based adult neuroregeneration
The irreversible loss of neurons in key cognitive circuits highlights a central therapeutic challenge: neurodegeneration in Alzheimer's disease (AD) outpaces the brain's intrinsic capacity for repair. Astrocyte-to-neuron (AtN) reprogramming has recently emerged as an appealing regenerative strategy because astrocytes, which are abundant, regionally distributed, and proliferative, represent an endogenous cellular reservoir from which new neurons might be generated in situ. Among the molecular targets proposed to induce AtN conversion, polypyrimidine tract-binding protein 1 (PTBP1) has attracted particular attention. PTBP1 is an RNA-binding protein that maintains non-neuronal splicing programs; its downregulation is a hallmark of neuronal differentiation during development. Early studies reported that suppressing PTBP1 in astrocytes or other glia could initiate neuronal transcriptional programs and produce cells resembling functional neurons in models of Parkinson's disease and retinal injury, sparking strong enthusiasm for PTBP1 as a single-factor reprogramming node. However, subsequent lineage-tracing studies yielded conflicting results, suggesting that PTBP1 depletion alone may be insufficient to drive genuine AtN conversion in the adult mammalian brain, raising concerns that some reported conversions reflected viral promoter leakage into pre-existing neurons.
A major technical hurdle in translating PTBP1-based reprogramming for therapeutic use is precise, efficient, and cell-type-selective delivery of the reprogramming agent to astrocytes in vivo while avoiding off-target perturbation of neurons and other cell types. Conventional PTBP1 knockdown methods, including viral shRNA, CRISPR, and antisense oligonucleotides, struggle to achieve astrocyte-restricted suppression without off-target effects on neurons, microglia, or peripheral tissues.
Recently, our group developed a Nano-ERASER system that can downregulate a specific protein by intracellular delivery of its corresponding antibodies via proteasome-mediated degradation, achieving Trim-Away in adult animals and in a disease model for the first time. Thus, we designed a Nano-ERASER-based Trim-Away platform to (1) effectively deliver anti-PTBP1 antibodies (aPTBP1) into astrocytes in the adult brain and (2) trigger rapid intracellular degradation of endogenous PTBP1 via TRIM21-mediated proteasomal clearance. The Trim-Away mechanism depletes target proteins directly at the protein level, bypassing limitations of transcriptional or RNA-targeting approaches and offering temporally precise control over protein levels. By combining blood-brain barrier (BBB)-targeting ligands with a polymer nanocarrier engineered for efficient endosomal escape and intracellular antibody release, the system aims to achieve transient, localized PTBP1 depletion in astrocytes while minimizing exposure to neurons and peripheral tissues. In doing so, it provides a rigorous platform to test whether transient PTBP1 ablation at the protein level is sufficient to engage neuronal splicing programs and promote astrocyte conversion in adult mammalian brain regions relevant to AD pathology.
Treatment with our new system significantly improves cognition, learning, and memory, demonstrating true functional reversal of AD-associated deficits in the 5XFAD mouse model of AD. By resolving the long-standing controversy surrounding PTBP1 reprogramming and establishing a translational biomaterials-based platform for in situ neuronal regeneration, this work introduces a transformative therapeutic paradigm aimed not only at slowing AD but at rebuilding the neuronal circuitry it destroys.
View the full article at FightAging
